Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Views & Analysis
european countries 3d illustration - european continent marked with flags

Resourcing HTA across Europe

With the European Commission looking to formally strengthen health technology assessment (HTA) across Member States, Leela Barham attempts to assess and benchmark the resources currently d

Views & Analysis
Businessman using touching circle global network payments online shopping and icon customer connection on virtual screen, m-banking, multichannel and omni channel

Can a virtual business model serve pharma?

Pharma has much to gain from leveraging components of a virtual business model, especially as an innovative way to work with experts and partners at the right moments throughout the product lif

Views & Analysis
Group of workers in uniform and helmets having talk in aisle

Gaining a clear view of supply chain visibility

In the pharma industry, companies need to know where products are at any point in the supply chain, but with one of the most complex systems of any industry, what are the pressure points and how can they be managed?

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more